Objectives: To describe the early uptake of edoxaban; the fourth direct oral anticoagulant (DOAC) to enter the market.
| INTRODUCTION
Direct oral anticoagulants (DOAC) have been introduced as alternatives to vitamin K-antagonists (VKA), primarily for stroke prevention in atrial fibrillation 1 and prevention and treatment of venous thromboembolism. 2 The thrombin inhibitor dabigatran etexilate was the first DOAC to receive European approval for use in atrial fibrillation in 2011, and it was soon followed by the two factor Xa inhibitors rivaroxaban and apixaban. Recently, another factor Xa-inhibitor, edoxaban, has been approved as the fourth DOAC in Europe, licensed for use in atrial fibrillation 3 as well as treatment and secondary prevention of pulmonary embolism and deep vein thrombosis. 4 Dabigatran was adopted very rapidly for the treatment of atrial fibrillation in both Europe 5 and USA. 6, 7 After their introduction, rivaroxaban and apixaban also achieved substantial market shares within their first year of availability, 5, 7, 8 at the expense of dabigatran, which over the years have become a less preferred anticoagulant choice, most likely due to its limited use in renal failure patients and the increased risk of gastrointestinal bleeding. 9, 10 The role for edoxaban in a market with 4 similar drugs is not immediately obvious.
Using trial data to indirectly compare edoxaban to the other DOACs, it is generally reported to have similar safety and efficacy. 11 Edoxaban holds the advantage of once-daily dosing and an overall low risk of bleeding. 12 However, gastrointestinal bleeding might also be more common among users of edoxaban than at least apixaban. 11 To understand the use and potential role of this new DOAC, we conducted a drug utilization study to characterize the early uptake of edoxaban. Using Danish nationwide health registries, we quantified the use of edoxaban in the first year after market entry and described the early users with regards to indication of use, previous anticoagulant experience, co-medication, and comorbidity. For comparison, this was also described for new users of dabigatran, rivaroxaban, and apixaban within the same period.
| METHODS
We identified all Danish users of edoxaban via the Danish National Prescription Registry. Using descriptive statistics and data from the Prescription Registry and the Danish National Patient Registry, we characterized these users regarding treatment indication, previous anticoagulant experience, co-medication, and comorbidity.
| Setting and data sources
The Danish National Health Service provides tax-supported health care, guaranteeing free and equal access to medical care by general practitioners and hospitals as well as partial reimbursement for prescribed medications. 13 For administration and maintenance of this health care system, numerous administrative and health registries have been established. These registries allow population-based studies covering all residents in Denmark (approximately 5.7 million). We obtained data from the National Prescription Registry, 14 the National Patient Registry, 15 and the Danish Civil Registration System. 16, 17 All data sources were linked using the unique civil registry number assigned to all Danish residents. 16 The National Prescription Registry 14 contains data on all prescription drugs filled by Danish residents since 1995. The data include the type of drug, date of filling, and quantity, whereas the dosing information and the indication for prescribing are not available. Drugs are categorized according to the Anatomic Therapeutic Chemical (ATC) index, 18 and the quantity dispensed for each prescription is described by the number and strength of the pharmaceutical entities (eg, tablets). 16, 17 contains data on addresses, migrations, and dates of death.
All codes and definitions applied within these data sources are provided in Appendix A and B.
| Study cohort
We identified all patients filling a prescription for edoxaban between there were only minor differences in prices between NOACs during the study period.
| Treatment indication
We considered 3 potential indications for DOAC use: atrial fibrillation, venous thromboembolism (including deep vein thrombosis and pulmonary embolism), and thromboprophylaxis after knee and hip replacement, although the latter is not an approved indication for edoxaban in Europe. Atrial fibrillation and venous thromboembolism were defined by relevant diagnoses registered at any time prior to DOAC initiation in the Patient Registry, while also including atrial fibrillation up to 90 days after DOAC initiation to allow for diagnostic lag. 5 Patients registered with both conditions were classified as atrial fibrillation unless the diagnosis of venous thromboembolism had been registered less than 1 year prior to DOAC initiation. All patients fulfilling the criteria for a recent knee or hip replacement was classified as such (a relevant procedure code registered in the period from 2 weeks before to 5 weeks after DOAC initiation).
| Previous anticoagulant experience
We assessed new DOAC users with respect to previous use of anticoagulants. Based on the time between the date of filling the index (cohort defining) DOAC prescription and the date of the most recent previous prescription filled for any oral anticoagulant (VKA or DOAC), patients were classified into current (<120 days), recent (120 days to 2 years), distant (>2 years), and never-use of oral anticoagulants at the day of cohort entry. For patients in the "current" category, ie,
KEY POINTS
What is already known about this subject?
• Edoxaban has recently entered the market as the fourth direct oral anticoagulant (DOAC).
• Overall, edoxaban is considered comparable to the other DOACs regarding safety and efficacy.
What might this study add?
• The early uptake of edoxaban is limited compared with the widespread use of other DOACs.
• Edoxaban is mainly used in patients with atrial fibrillation and, in general, users of edoxaban are similar to patients using other DOACs.
• As an important exception, use of edoxaban is mainly confined to patients with previous anticoagulant experience, with the majority switching to edoxaban directly from other anticoagulant treatment, both vitamin K-antagonists and other DOACs.
patients seemingly switching to edoxaban from active anticoagulant treatment, we also registered which anticoagulant was the last one filled prior to switching.
| Co-medication and comorbidity
We included chronic diseases associated with an increased risk of Atrial (Table 4) . Defined as the time from inclusion (index prescription) to the recent prescription for any oral anticoagulant (VKA or DOAC): current (<120 days), recent (120 days to 2 years), distant (>2 years), and never-use.
| DISCUSSION
We have documented a slow but increasing initial uptake of edoxaban and have described the characteristics of early edoxaban users in Denmark within the first year following market entry. Edoxaban is primarily used in atrial fibrillation and appears to be used in patients that are generally similar to those using other DOACs, with the important exception that the majority of new users are switched to edoxaban from other oral anticoagulant therapies.
Compared with the study population in ENGAGE AF trial, 3 "reallife" users of edoxaban with AF had a similar median age (75 years in the present study vs 72 in the trial) but at the same time lower frequencies of comorbid conditions, such as prior stroke/TIA (9% vs 28% in the trial), diabetes (11% vs 36%), and aspirin use (14% vs 29%). Despite the lower frequency of comorbidity in patients initiating edoxaban, the proportion of patients using a reduced dose in our population (31%) was higher than the proportion fulfilling the criteria for dose reduction in the ENGAGE AF trial (25%). Although assessment of the appropriateness of dosing was not possible in the present study, this may indicate underdosing with edoxaban in some patients. Physicians withholding 23, 24 or underdosing 25, 26 anticoagulation in order to avoid bleeding have previously been reported in real-life studies on Defined as the time from inclusion (index prescription) to the recent prescription for any oral anticoagulant (VKA or DOAC): current (<120 days), recent (120 days to 2 years), distant (>2 years), and never-use.
b Dose is based on the prescribed tablet strength.
patients treated with DOACs. Importantly, low-dose edoxaban was inferior to warfarin with regards to prevention of ischaemic stroke in the ENGAGE AF trial. the edoxaban group is selective prescribing, ie, the channeling of edoxaban away from individuals at increased risk of gastrointestinal bleeding, as this is an important safety concern related to edoxaban.
12
Regardless of the underlying cause, these differences in patient characteristics between users of different DOACs must be kept in mind when conducting and interpreting observational studies assessing the comparative effectiveness and safety of DOACs. 28, 29 We have shown that the uptake of edoxaban has been considerably slower than what was seen for the other DOACS, especially dabigatran, which was the first DOAC entering the market. 5 The rapid uptake of dabigatran was likely explained by the novel availability of a supposedly safer anticoagulant treatment option with no need for monitoring and less interactions with food and co-medication. This is further supported by the substantially larger proportion of patients without current anticoagulant use who initiated treatment with dabigatran during the first 4 months following market entry of dabigatran compared with the first edoxaban initiators (59% vs 23%). 30 Thus, dabigatran was initially used both in patients newly diagnosed with an indication for anticoagulant therapy, 31 in patients previously found unsuitable for VKA therapy, 23 and in switchers from other anticoagulants. 32 By contrast, the early uptake of edoxaban has almost exclusively been in the latter group of patients (ie, switchers), which is consistent with prior findings on the utilization patterns of newly introduced drugs. 33 Incidentally, the ENGAGE AF trial is the only DOAC trial in AF reporting previous VKA experience to modify the effect of edoxaban treatment. 34 For patients with previous VKA use, the advantageous effect of high-dose edoxaban compared with VKA was attenuated, while low-dose edoxaban was inferior to warfarin among those with previous VKA use. 35 Considering the availability of four relatively similar drugs, one may speculate on the role for the fourth DOAC to enter the market.
In terms of preventing stroke and systemic embolism, subgroup analyses of the ENGAGE AF trial have reported edoxaban to be at least as effective as warfarin in patients with a history of ischaemic stroke or transient ischaemic attack, 36 patients with heart failure (NYHA III/ IV), 37 East Asian patients, 38 and the elderly, 39 has reported a signal of higher thromboembolic rates with edoxaban compared with warfarin. 42 The primary strength of our study is the use of high-quality data on prescription records 14 and inpatient diagnoses 15 and the timely analysis with only a few months lag in the reporting of edoxaban uptake. Further, the use of data on prescription fills, as opposed to prescriptions issued, increases the likelihood that we are in fact describing patients that ultimately uses the drug in question. 43 The main limitation of our study is the limited data on indications for use, and consequently a large proportion of patients (31%-41% across DOACs)
was denoted with unknown indication for treatment. As these patients were more commonly new anticoagulant users, the missing indications for DOAC therapy may be explained by lag time between diagnosis and registration of the indication, as shown in prior studies. 5 Further, some patients might be managed solely in primary care, thus never receiving a hospital diagnosis (ie, the basis of our classification). More likely, the lack of diagnoses is a product of suboptimal coding practices within the hospitals. Importantly, these DOAC users without a registered indication were older, more frequently had a history of ischaemic stroke, and more often received low-dose DOAC compared with DOAC users with a registered indication. Therefore, the exclusion of DOAC users without a registered indication may constitute an important selection bias in observational studies based on the Danish health care registries, as pointed out previously. 5, 27 In conclusion, we have documented the initial uptake of edoxaban. 
